Molecular Interactions of Thrombin

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Seminars in Thrombosis and Hemostasis

• Publication date

  1996-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1055/s-2007-998998PMID 8807707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An ambiguous structure of a DNA 15-mer thrombin complex.

  1996cited by this paper
• The Na+ Binding Site of Thrombin (*)

  1995cited by this paper
• Structure of a retro-binding peptide inhibitor complexed with human alpha-thrombin.

  1995cited by this paper
• An allosteric switch controls the procoagulant and anticoagulant activities of thrombin.

  1995cited by this paper
• Thrombin Specificity

  1995cited by this paper
• Structures of the noncovalent complexes of human and bovine prothrombin fragment 2 with human PPACK-thrombin.

  1994cited by this paper
• The structure of alpha-thrombin inhibited by a 15-mer single-stranded DNA aptamer.

  1994cited by this paper
• Identification of basic amino acid residues in thrombin essential for heparin-catalyzed inactivation by antithrombin III.

  1994cited by this paper
• Retro-binding tripeptide thrombin active-site inhibitors: discovery, synthesis, and molecular modeling.

  1994cited by this paper
• Molecular recognition by thrombin. Role of the slow-->fast transition, site-specific ion binding energetics and thermodynamic mapping of structural components.

  1994cited by this paper
• Heparin cofactor II is regulated allosterically and not primarily by template effects. Studies with mutant thrombins and glycosaminoglycans.

  1994cited by this paper
• Crystallographic structures of thrombin complexed with thrombin receptor peptides: existence of expected and novel binding modes.

  1994cited by this paper
• Structure of the hirulog 3-thrombin complex and nature of the S' subsites of substrates and inhibitors.

  1994cited by this paper
• Glycosaminoglycan contributions to both protein C activation and thrombin inhibition involve a common arginine-rich site in thrombin that includes residues arginine 93, 97, and 101.

  1994cited by this paper
• The structure of residues 7-16 of the A alpha-chain of human fibrinogen bound to bovine thrombin at 2.3-A resolution.

  1994cited by this paper
• Kringle‐kringle interactions in multimer kringle structures

  1994cited by this paper
• Three-dimensional solution structure of the thrombin-binding DNA aptamer d(GGTTGGTGTGGTTGG).

  1994cited by this paper
• The isomorphous structures of prethrombin2, hirugen–, and PPACK–thrombin: Changes accompanying activation and exosite binding to thrombin

  1994cited by this paper
• Structures of thrombin complexes with a designed and a natural exosite peptide inhibitor.

  1994cited by this paper
• Structure of a nonadecapeptide of the fifth EGF domain of thrombomodulin complexed with thrombin.

  1994cited by this paper
• Thrombin-bound structure of an EGF subdomain from human thrombomodulin determined by transferred nuclear Overhauser effects.

  1994cited by this paper
• The tertiary structure of a DNA aptamer which binds to and inhibits thrombin determines activity.

  1993cited by this paper
• Epidermal growth factor-like modules

  1993cited by this paper
• Alanine-scanning mutagenesis of the epidermal growth factor-like domains of human thrombomodulin identifies critical residues for its cofactor activity.

  1993influential reference
• Structure of human des(1-45) factor Xa at 2.2 A resolution.

  1993cited by this paper
• A player of many parts: the spotlight falls on thrombin's structure.

  1993cited by this paper
• Crystal structure of the complex of human α‐thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin—2 and hirutonin—6

  1993cited by this paper
• Active site and exosite binding of alpha-thrombin.

  1993cited by this paper
• Thrombin-fibrinogen interaction: pH dependence and effects of the slow-->fast transition.

  1993cited by this paper
• The interaction of thrombin with fibrinogen. A structural basis for its specificity.

  1992cited by this paper
• Selection of single-stranded DNA molecules that bind and inhibit human thrombin

  1992cited by this paper
• Thrombin is a Na(+)-activated enzyme.

  1992cited by this paper
• Electrostatic interactions in the association of proteins: An analysis of the thrombin–hirudin complex

  1992cited by this paper
• The refined 1.9‐Å X‐ray crystal structure of d‐Phe‐Pro‐Arg chloromethylketone‐inhibited human α‐thrombin: Structure analysis, overall structure, electrostatic properties, detailed active‐site geometry, and structure‐function relationships

  1992cited by this paper
• Thrombin-specific inhibition by and slow cleavage of hirulog-1.

  1992cited by this paper
• Refined structure of the hirudin-thrombin complex.

  1991cited by this paper
• Structure of the hirugen and hirulog 1 complexes of alpha-thrombin.

  1991cited by this paper
• Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin.

  1990cited by this paper
• Crystal structure of the thrombin‐hirudin complex: a novel mode of serine protease inhibition.

  1990cited by this paper
• Equilibrium binding of thrombin to recombinant human thrombomodulin: effect of hirudin, fibrinogen, factor Va, and peptide analogues.

  1990cited by this paper
• Further localization of binding sites for thrombin and protein C in human thrombomodulin.

  1990cited by this paper
• The structure of a complex of recombinant hirudin and human alpha-thrombin.

  1990cited by this paper
• Structural and functional properties of human alpha-thrombin, phosphopyridoxylated alpha-thrombin, and gamma T-thrombin. Identification of lysyl residues in alpha-thrombin that are critical for heparin and fibrin(ogen) interactions.

  1989cited by this paper
• Kinetics of the inhibition of thrombin by hirudin.

  1986cited by this paper
• Evidence that human alpha-thrombin is a monovalent cation-activated enzyme.

  1980cited by this paper
• A two-step fibrinogen–fibrin transition in blood coagulation

  1978cited by this paper
• Structure of N-terminal Fragments of Fibrinogen and Specificity of Thrombin

  1967cited by this paper

• Aptamer-Assisted DNA SELEX: Dual-Site Targeting of a Single Protein.

  2025cites this paper
• Synthetic Peptide-Based Thrombin Inhibitors: a Potential Anticoagulant Approach

  2025cites this paper
• Beyond Anticoagulation: A Comprehensive Review of Non-Vitamin K Oral Anticoagulants (NOACs) in Inflammation and Protease-Activated Receptor Signaling

  2024cites this paper
• In Vitro Antithrombotic, Hematological Toxicity, and Inhibitor Studies of Protocatechuic, Isovanillic, and p-Hydroxybenzoic Acids from Maclura tricuspidata (Carr.) Bur

  2022cites this paper
• Neuropharmacology in the Intensive Care Unit.

  2022cites this paper
• Exosite Binding in Thrombin: A Global Structural/Dynamic Overview of Complexes with Aptamers and Other Ligands

  2021cites this paper
• Thrombin: An Approach to Developing a Higher-Order Reference Material and Reference Measurement Procedure for Substance Identity, Amount, and Biological Activities

  2020influential citation
• Revisiting antithrombotic therapeutics; sculptin, a novel specific, competitive, reversible, scissile and tight binding inhibitor of thrombin

  2017cites this paper
• Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion

  2015cites this paper
• Multifunctional Roles o f Thrombin *

  2015cites this paper
• Pathology consultation on monitoring direct thrombin inhibitors and overcoming their effects in bleeding patients.

  2013influential citation
• Differential profiles of thrombin inhibitors (heparin, hirudin, bivalirudin, and dabigatran) in the thrombin generation assay and thromboelastography in vitro

  2013cites this paper
• Prevention and treatment of venous thromboembolism and pulmonary embolism: the role of novel oral anticoagulants.

  2012cites this paper
• Direct Thrombin Inhibitors’ Potential Efficacy in Alzheimer’s Disease

  2012cites this paper
• Novel oral anticoagulants: focus on the direct factor Xa inhibitor darexaban

  2012cites this paper
• Heparin-induced thrombocytopenia in the pediatric population: a review of current literature.

  2012cites this paper
• Development of a fast and simple liquid chromatography-tandem mass spectrometry method for the quantitation of argatroban in patient plasma samples.

  2012cites this paper
• Synthesis and radical polymerisation of methacrylic monomers with crown ethers or their dipodal counterparts in the pendant structure

  2011cites this paper
• Direct thrombin inhibitors.

  2011cites this paper
• Recent progress in antithrombotic therapy for atrial fibrillation.

  2011cites this paper
• Acrylic copolymers with pendant 1,2,4‐triazole moieties as colorimetric sensory materials and solid phases for the removal and sensing of cations from aqueous media

  2011cites this paper
• Working with water insoluble organic molecules in aqueous media: fluorene derivative-containing polymers as sensory materials for the colorimetric sensing of cyanide in water

  2011cites this paper
• Dabigatran: Review of Pharmacology and Management of Bleeding Complications of This Novel Oral Anticoagulant

  2011cites this paper
• Fluorogenic and Chromogenic Polymer Chemosensors

  2011cites this paper
• Application in the Field of Biomedical Materials

  2010cites this paper
• Bivalent ligands with long nanometer-scale flexible linkers.

  2009cites this paper
• Thrombin physiology and pathophysiology.

  2009cites this paper
• Computational Modeling And Simulation Of Thrombus Formation

  2009cites this paper
• Molecularly imprinted polymers with specific recognition for macromolecules and proteins

  2008cites this paper
• Will Warfarin Soon Be Passé? New Approaches to Stroke Prevention in Atrial Fibrillation

  2008cites this paper
• Computationally Derived Points of Fragility of a Human Cascade Are Consistent with Current Therapeutic Strategies

  2007cites this paper
• Inhibition of thrombin activity by prothrombin activation fragment 1.2

  2007cites this paper
• Vapor-based polymer coatings for potential biomedical applications

  2006cites this paper
• Bivalirudin in percutaneous coronary intervention

  2006cites this paper
• L'impiego clinico di una nuova classe di farmaci anticoagulanti: gli inibitori diretti della trombina

  2006cites this paper
• UvA-DARE (Digital Academic Repository) Direct thrombin inhibitors [review]

  2005cites this paper
• Direct thrombin inhibitors.

  2005cites this paper
• The direct thrombin inhibitors: their role and use for rational anticoagulation.

  2005cites this paper
• In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.

  2005cites this paper
• Direct Thrombin Inhibitor Use During Percutaneous Coronary Intervention

  2005cites this paper
• Molecularly imprinted polyacrylamide polymers and copolymers with specific recognition for serum proteins

  2005cites this paper
• Strategies for Patients ndergoing Percutaneous Coronary ntervention : Unfractionated Heparin , ow-Molecular-Weight Heparins , and irect Thrombin Inhibitors

  2004cites this paper
• Anticoagulation strategies for patients undergoing percutaneous coronary intervention: unfractionated heparin, low-molecular-weight heparins, and direct thrombin inhibitors.

  2004cites this paper
• Blood coagulation.

  2003cites this paper
• Design, parallel synthesis, and crystal structures of pyrazinone antithrombotics as selective inhibitors of the tissue factor VIIa complex.

  2003cites this paper
• Direct thrombin inhibitors

  2003cites this paper
• Evaluation of DNA aptamers directed to thrombin as potential thrombus imaging agents.

  2003cites this paper
• Thrombin functions during tissue factor-induced blood coagulation.

  2002cites this paper
• Direct thrombin inhibitors.

  2002cites this paper
• [Actions of Antithrombin (AT): experimental and clinical results].

  2001cites this paper
• Antithrombin (AT) - Wirkung: Experimentelle und klinische Ergebnisse

  2001cites this paper
• Bioactive immobilization of r-hirudin on CVD-coated metallic implant devices.

  2001cites this paper
• Immobilization of the thrombin inhibitor r-hirudin conserving its biological activity

  2001cites this paper
• Structure of human alpha-thrombin complexed with RWJ-51438 at 1.7 A: unusual perturbation of the 60A-60I insertion loop.

  2000cites this paper
• Modelling of Factor Xa‐inhibitor complexes: a computational flexible docking approach

  1999cites this paper
• Site-directed Mutagenesis of the Calcium-binding Site of Blood Coagulation Factor XIIIa*

  1999cites this paper
• Small, noncovalent serine protease inhibitors

  1999cites this paper
• Multifunctional roles of thrombin.

  1999cites this paper
• Structures of thrombin retro-inhibited with SEL2711 and SEL2770 as they relate to factor Xa binding.

  1999cites this paper
• Bound structures of novel P3-P1' beta-strand mimetic inhibitors of thrombin.

  1999cites this paper
• The coagulation pathway and antithrombotic strategies

  1999cites this paper
• A dimeric form of prothrombin on membrane surfaces.

  1998cites this paper
• Thrombin inhibitor design.

  1998cites this paper
• Role of blood clot formation on early edema development after experimental intracerebral hemorrhage.

  1998cites this paper
• Current concepts of coagulation and fibrinolysis.

  1998cites this paper